


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

**ANNOUNCEMENT PURSUANT TO
RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES**

This announcement is made by C-MER Eye Care Holdings Limited (the “**Company**”) pursuant to Rules 13.51B(2) and 13.51(2) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

On 26 August 2020, the board of directors of the Company (the “**Board**”) was informed by Dr. Lee Yau Wing Vincent (“**Dr. Lee**”), an executive director of the Company, that he had received a letter dated 10 August 2020 from The Medical Council of Hong Kong (the “**Medical Council**”), in which the Inquiry Panel of the Medical Council reprimanded Dr. Lee in respect of his failure to prevent the use of the title “視網膜黃斑點手術專家”, which was not a quotable qualification approved by the Medical Council and/or was misleading to the public, in an advertisement or article published by a local newspaper on 24 September 2018 (the “**Order**”).

Dr. Lee has confirmed that the article was published in relation to a promotion of a public event at which Dr. Lee was the invited speaker. Our Hong Kong Foundation (團結香港基金), the organiser of the event did not inform Dr. Lee of the use of the above title or the publication of the advertisement in the newspaper for the above event. Nevertheless, the Inquiry Panel considered that Dr. Lee was guilty of misconduct in a professional respect and ordered him to be reprimanded.

The Board assessed the Order and is of the view that Dr. Lee would be suitable to act as a director of the Company, taking into account that (i) the matter does not involve any fraudulent or integrity issue on the part of Dr. Lee; and (ii) the Order does not affect the qualification of Dr. Lee acting as director under the laws of Hong Kong. Dr. Lee remains as a practising doctor of the Group, and the Board considers that the above incident has not had and will not have any impact on the business operation and financial position of the Company.

The Board confirms that the above order against Dr. Lee is unrelated to the Company and its subsidiaries. Save as disclosed above, the Board is not aware of any other information which is required to be disclosed pursuant to Rules 13.51B(2) and 13.51(2) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu Dennis JP
Chairman and Chief Executive Officer and Executive Director

Hong Kong, 2 September 2020

As of the date of this announcement, the Board comprises four executive directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and four independent non-executive directors, namely, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.